Abstract
Nanoparticles, structures of less than 200 nm capable of delivering pharmacotherapeutics
to sites of disease, have shown great promise for the treatment of many disease states.
While no nanoparticle therapies for deep vein thrombosis are currently approved by
the Food and Drug Administration, many of the unique features of these therapies have
the potential to treat both deep vein thrombosis and its most significant sequela,
postthrombotic syndrome, while limiting the hemorrhagic complications of current antithrombotic
therapies. Nanoparticles are complex structures with several important variables that
must be considered to engineer effective therapies. This article will review the structure
and engineering of nanoparticles, as well as promising molecular targets for future
investigation.
Keywords
deep vein thrombosis - nanoparticle therapy - interventional radiology
